This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1izi

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1izi.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1izi.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1izi| PDB=1izi | SCENE= }}
{{STRUCTURE_1izi| PDB=1izi | SCENE= }}
-
'''Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants'''
+
===Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants===
-
==Overview==
+
<!--
-
Protease inhibitors (PIs) are an important class of drugs for the treatment of HIV infection. However, in the course of treatment, resistant viral variants with reduced sensitivity to PIs often emerge and become a major obstacle to successful control of viral load. On the basis of a compound equipotently inhibiting HIV-1 and 2 proteases (PR), we have designed a pseudopeptide inhibitor, QF34, that efficiently inhibits a wide variety of PR variants. In order to analyze the potency of the inhibitor, we constructed PR species harboring the typical (signature) mutations that confer resistance to commercially available PIs. Kinetic analyses showed that these mutated PRs were inhibited up to 1,000-fold less efficiently by the clinically approved PIs. In contrast, all PR species were effectively inhibited by QF34. In a clinical study, we have monitored 30 HIV-positive patients in the Czech Republic undergoing highly active antiretroviral therapy, and have identified highly PI resistant variants. Kinetic analyses revealed that QF34 retained its subnanomolar potency against multi-drug resistant PR variants. X-ray crystallographic analysis and molecular modeling experiments explained the wide specificity of QF34: this inhibitor binds to the PR in an unusual manner, thus avoiding contact sites that are mutated upon resistance development, and the unusual binding mode and consequently the binding energy is therefore preserved in the complex with a resistant variant. These results suggest a promising route for the design of second-generation PIs that are active against a variety of resistant PR variants.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12460574}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12460574 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12460574}}
==About this Structure==
==About this Structure==
Line 45: Line 49:
[[Category: Subsite binding]]
[[Category: Subsite binding]]
[[Category: Triple mutant]]
[[Category: Triple mutant]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 20:37:09 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 14:16:11 2008''

Revision as of 11:16, 1 July 2008

Image:1izi.png

Template:STRUCTURE 1izi

Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants

Template:ABSTRACT PUBMED 12460574

About this Structure

1IZI is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains., Weber J, Mesters JR, Lepsik M, Prejdova J, Svec M, Sponarova J, Mlcochova P, Skalicka K, Strisovsky K, Uhlikova T, Soucek M, Machala L, Stankova M, Vondrasek J, Klimkait T, Kraeusslich HG, Hilgenfeld R, Konvalinka J, J Mol Biol. 2002 Dec 6;324(4):739-54. PMID:12460574

Page seeded by OCA on Tue Jul 1 14:16:11 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1izi"
Personal tools